In this month’s Voyager, learn how Veristat is committed to easing the burden on patients for even the most complex studies with fully customized DCT solutions.
Making DCTs a Successful Reality for Complex Studies
Decentralized clinical trials (DCTs) have moved into the limelight in today's post pandemic world. While there are many ways to define a DCT (virtual, home-based, remote, hybrid, adaptive) there is only one way at Veristat: integrated.
Our virtual approach is fully integrated into our day-to-day operations across all solutions. In this month’s Voyager, learn how Veristat is committed to easing the burden on patients for even the most complex studies with fully customized DCT solutions.
Press release: Veristat joins the Decentralized Trials & Research Alliance (DTRA)
Veristat has joined an alliance of over 120 life sciences and healthcare organizations whose mission is to accelerate the broad adoption of patient-focused, decentralized clinical trials and research.
Audio Infographic: Defining the Value of Decentralized Clinical Trials
DCTs offer many benefits for complex trials, such as for rare disease trials. Gain a better understanding of their advantages by listening to Veristat’s Shaheen Limbada, EVP of Innovation and Strategy, as he describes several use cases and the benefits they offer.
On-demand Webinar: Navigating the Patient Experience When Pivoting to a Virtual Model Mid-Study
Completing a natural history study for ultra-rare diseases can be critical to understanding the disease and its progression. Here, we explore the challenges of designing and running an extraordinarily complex natural history study which needed to pivot to virtual patient visits mid-way through the data collection process.
Podcast: Orphan Drug Designations and Orphan Subsets
Orphan diseases are rare, by definition, with patient populations often widely distributed geographically, making them prime candidates for decentralized trials. Listen as members of Veristat’s regulatory team shed light on orphan drug designation classifications and the strategic use of subsets in study design.
